A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF, A Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With 5-Fluorouracil and Leucovorin Chemotherapy in Subjects With Metastatic Colorectal Cancer Who Are Not Optimal Candidates for First-Line CPT-11.

Trial Profile

A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF, A Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With 5-Fluorouracil and Leucovorin Chemotherapy in Subjects With Metastatic Colorectal Cancer Who Are Not Optimal Candidates for First-Line CPT-11.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 24 Sep 2005 New trial record.
    • 01 Jun 2005 Primary endpoint 'Overall survival duration' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top